ClinicalTrials.gg
RecruitingNCT01193088INC-6602Updated Oct 27, 2026

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

An observational study in Charcot-Marie-Tooth Disease, Type Ia (Disorder) and HMSN, sponsored by University of Iowa. Recruiting at 24 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Iowa · Observational

How we know

From the registry’s dates

  • Started May 2010; still recruiting 16 years 6 months later.
Updated Oct 16, 2026First site in CyprusPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,050
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Charcot-Marie-Tooth Disease with a site in United States — 9 open to participants now, 14 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · United States.

Planned enrollment
6th of 21
1,050 · median 291
Started
2010
with 2 others
Observational
21 of 41
8 open now
Primary completion
2030-12
later than 7 of 13 live
Registered
3rd of 41
by date
Lead sponsor
4 of 41
University of Iowa

Among the 41 studies in Charcot-Marie-Tooth Disease with a site in United States, this one is the 6th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2010, is one of 21 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 3rd registered.

Charcot-Marie-Tooth Disease

115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.

Browse Charcot-Marie-Tooth Disease studies →

Open to participants now

9 of the 41 studies in Charcot-Marie-Tooth Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Charcot-Marie-Tooth Disease with a site in United States, or all of them as a file.
02

Study summary

This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.

Read the detailed description

This project is to understand modifier genes and how they influence the severity of disease expression, along with identifying new forms of CMT which have not been genetically determined. Subjects who are eligible will either have CMT type 1A (CMT1A) or an unknown form of CMT. Blood will be drawn and sent to the University of Miami where they receive the coded sample and process it through exome sequencing. Subjects will be told that this is optional.

03

Conditions studied

  • Charcot-Marie-Tooth Disease, Type Ia (Disorder)
  • HMSN

Keywords

  • CMT
  • CMT1A
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients participating in Inherited Neuropathies Consortium (INC)-6601 and meeting eligibility criteria for this study will be recruited.

Eligibility criteria

Inclusion Criteria:

  • Patients:

    o Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed hereditary neuropathy, in the opinion of the site investigator.

  • Controls:

    • Must be a family member of a CMT patient who is enrolled in the 6602.
    • AND one of the following:
    • Does not have a peripheral neuropathy, in the opinion of the site investigator.
    • OR is suspected to have a peripheral neuropathy, but has not been examined at an INC site.

CMT1A Modifier Study

Inclusion Criteria:

  • Patient has a documented PMP22 duplication

AND/OR

  • Patient has a first or second degree relative (parent, child, sibling, half-sibling, aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented PMP22 duplication AND a clear link between that family member and the affected patient AND a phenotype consistent with CMT1A.
  • A clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a PMP22 duplication, and the parent does not have any signs, symptoms, or electrophysiology consistent with CMT1A, there is no clear link.
  • In cases where clear links are not available, genetic testing is required for the patient or the first degree family member who is not clearly affected.

Exclusion Criteria

  • All Patients: Must not have known neuropathy from a non-genetic source, such as chemotherapies (i.e., Vincristine, Taxol, Cisplatin), diabetes, alcoholism.
  • CMT Exome Project Patients ONLY: Must not have a genetically confirmed form of CMT
  • All Participants: Does not wish to participate or does not sign a consent form.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,050 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • CMT1A

    Families/people with genetically defined CMT1A

  • Genetically undefined CMT

    Families/people with genetically undefined CMT with common causes ruled out.

06

What researchers measure

Primary outcomes

  1. Charcot Marie Tooth disease type 1A (CMT1A) gene modifiers

    While the same genetic change - an extra copy of PMP22 - causes CMT1A by definition, it is unclear why some people have more severe symptoms and some have less severe. We are looking for genetic modifiers - changes in the DNA that may be causing the differences in symptoms.

    Time frame: once

  2. New genetic causes of CMT

    At least 33% of people with CMT have an unknown or genetically un-found form of the condition. We are looking for additional genes that cause CMT when mutated.

    Time frame: Once

07

Study locations

24 of 24 sites recruiting
08

References and documents

Publications

  • Montenegro G, Powell E, Huang J, Speziani F, Edwards YJ, Beecham G, Hulme W, Siskind C, Vance J, Shy M, Zuchner S. Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol. 2011 Mar;69(3):464-70. doi: 10.1002/ana.22235. Epub 2011 Jan 20. PubMed 21254193 ↗

Individual participant data

Plan to share: Yes — De-identified RDCRN data is submitted to an ORDR-designated repository. For the current grant cycle, that repository has been dbGaP

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: (For Observational/Longitudinal/Natural History/Epidemiology studies): For the current grant cycle, available data will be released to the repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first.

Access criteria: - For the current grant cycle, once de-identified data is posted on dbGaP, a summary of the study is posted and individual participant data is accessed via a request through dbGaP.

Data sharing details ↗ · www.ncbi.nlm.nih.gov

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2010 (actual). Primary completion is estimated for Dec 2030, 247 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Dec 2030 and completion Dec 2026 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2010
First posted
Sep 1, 2010
StartActual
May 2010
Primary completionEst.
Dec 2030was Dec 2026
CompletionEst.
Dec 2030was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed — first site in Cyprus
Show 3 added (1 United States, 1 Cyprus, 1 United Kingdom)
  • Nationwide Children's Hospital · Columbus, United States
  • The Cyprus Institute of Neurology & Genetics · Nicosia, Cyprus
  • Great Ormond Street Hospital · London, United Kingdom
Show 1 removed
  • Dubowitz Neuromuscular Centre · London, United Kingdom
Oct 16, 2026
Primary completion
Dec 2026→Dec 2030
Oct 16, 2026
Study completion
Dec 2026→Dec 2030
Oct 16, 2026
Eligibility
5 inclusion criteria removed; 1 exclusion criterion removed; 9 criteria edited, 6 added
What changed in the criteria
  • AddedInclusion Criteria:
  • AddedPatients:
  • EditedPatient haso Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed genetichereditary neuropathy, in the opinion of the site investigator or genetic counsellor.
  • AddedControls:
  • EditedPerson isMust be a family member of a CMT patient who is enrolled in the CMT Exome Project6602.
  • EditedPerson doesDoes not have a peripheral neuropathy, in the opinion of the site investigator or genetic counsellor.
  • EditedPersonOR is suspected to have a peripheral neuropathy, but has not been examined at an INC site.
  • EditedInclusion Criteria: CMT1A Gene Modifier Study
  • AddedInclusion Criteria:
  • EditedPatient has a documented PMP22 duplication. AND/OR
  • EditedAND/OR
  • AddedExclusion Criteria
  • EditedAll Patients with: Must not have known neuropathy from a non-genetic source, such as chemotherapies (i.e., Vincristine, Taxol, Cisplatin), diabetes, alcoholism will be evaluated independently so that genetic contributions to their effects on CMT1A phenotypes can also be analyzed.
  • AddedCMT Exome Project Patients ONLY: Must not have a genetically confirmed form of CMT
  • EditedPatient doesAll Participants: Does not wish to participate or does not sign a consent form.
Inclusion criteria
  • RemovedAll patients must agree to take part in the study and sign a consent form. A teenager (age 13-17 years) considering enrolling must agree to take part in the study and sign an assent form (depending on local ethics committee requirements).
  • RemovedAdditional inclusion criteria are described below.
  • RemovedInclusion Criteria - Controls for CMT Exome Project
  • RemovedPatients must have at least one of the following:
  • RemovedInclusion Criteria - Patients for CMT Exome Project
Exclusion criteria
  • RemovedFor CMT Exome Project, patient has a genetically confirmed form of CMT (i.e. mutation in MFN2 causing CMT2A, mutation in GARS causing CMT2D, etc.).
Oct 16, 2026
Contact
Study contact changed: U•••@uiowa.edu · •••6362→U•••@uiowa.edu · •••6362. See the current contact
Oct 16, 2026
Site contacts
Changed at 11 sites. See the sites
Show 11 sites
  • Stanford University · Palo Alto, United StatesContact v•••@stanford.edu · •••5588→m•••@stanford.edu
  • University of Miami · Miami, United StatesContact m•••@med.miami.edu; · •••2550→l•••@med.miami.edu
  • Harvard/Massachusetts General Hospital · Boston, United StatesContact n•••@mgh.harvard.edu · •••6996→l•••@mgh.harvard.edu
  • University of Minnesota · Maple Grove, United StatesContact h•••@umn.edu · •••5978→f•••@umn.edu
  • University of North Carolina · Chapel Hill, United StatesContact a•••@neurology.unc.edu · •••8175→s•••@neurology.unc.edu
  • University of Pennsylvania · Philadelphia, United StatesContact p•••@pennmedicine.upenn.edu→d•••@pennmedicine.upenn.edu
  • Houston Methodist Hospital · Houston, United StatesContact added (no phone or email listed)
  • Children's Hospital of Westmead · Sydney, AustraliaContact person changed (no phone or email listed)
  • The Hospital for Sick Children · Toronto, CanadaContact none listed→•••6831
  • C. Besta Neurological Institute · Milan, ItalyContact d•••@istituto-besta.it · •••3001→e•••@istituto-besta.it
  • National Hospital of Neurology and Neurosurgery · London, United KingdomContact •••3611→none listed
across 2 updates, Oct 16, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Hospital of Neurology and Neurosurgery · London, United KingdomContact •••3611→none listed
  2. Oct 16, 2026
    3 sites added, 1 site removed — first site in Cyprus
    Show 3 added (1 United States, 1 Cyprus, 1 United Kingdom)
    • Nationwide Children's Hospital · Columbus, United States
    • The Cyprus Institute of Neurology & Genetics · Nicosia, Cyprus
    • Great Ormond Street Hospital · London, United Kingdom
    Show 1 removed
    • Dubowitz Neuromuscular Centre · London, United Kingdom
    Primary completion Dec 2026→Dec 2030
    Study completion Dec 2026→Dec 2030
    Eligibility 5 inclusion criteria removed; 1 exclusion criterion removed; 9 criteria edited, 6 added
    What changed in the criteria
    • AddedInclusion Criteria:
    • AddedPatients:
    • EditedPatient haso Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed genetichereditary neuropathy, in the opinion of the site investigator or genetic counsellor.
    • AddedControls:
    • EditedPerson isMust be a family member of a CMT patient who is enrolled in the CMT Exome Project6602.
    • EditedPerson doesDoes not have a peripheral neuropathy, in the opinion of the site investigator or genetic counsellor.
    • EditedPersonOR is suspected to have a peripheral neuropathy, but has not been examined at an INC site.
    • EditedInclusion Criteria: CMT1A Gene Modifier Study
    • AddedInclusion Criteria:
    • EditedPatient has a documented PMP22 duplication. AND/OR
    • EditedAND/OR
    • AddedExclusion Criteria
    • EditedAll Patients with: Must not have known neuropathy from a non-genetic source, such as chemotherapies (i.e., Vincristine, Taxol, Cisplatin), diabetes, alcoholism will be evaluated independently so that genetic contributions to their effects on CMT1A phenotypes can also be analyzed.
    • AddedCMT Exome Project Patients ONLY: Must not have a genetically confirmed form of CMT
    • EditedPatient doesAll Participants: Does not wish to participate or does not sign a consent form.
    Inclusion criteria
    • RemovedAll patients must agree to take part in the study and sign a consent form. A teenager (age 13-17 years) considering enrolling must agree to take part in the study and sign an assent form (depending on local ethics committee requirements).
    • RemovedAdditional inclusion criteria are described below.
    • RemovedInclusion Criteria - Controls for CMT Exome Project
    • RemovedPatients must have at least one of the following:
    • RemovedInclusion Criteria - Patients for CMT Exome Project
    Exclusion criteria
    • RemovedFor CMT Exome Project, patient has a genetically confirmed form of CMT (i.e. mutation in MFN2 causing CMT2A, mutation in GARS causing CMT2D, etc.).
    Contact Study contact changed: U•••@uiowa.edu · •••6362→U•••@uiowa.edu · •••6362. See the current contact
    Site contacts Changed at 10 sites. See the sites
    Show 10 sites
    • Stanford University · Palo Alto, United StatesContact v•••@stanford.edu · •••5588→m•••@stanford.edu
    • University of Miami · Miami, United StatesContact m•••@med.miami.edu; · •••2550→l•••@med.miami.edu
    • Harvard/Massachusetts General Hospital · Boston, United StatesContact n•••@mgh.harvard.edu · •••6996→l•••@mgh.harvard.edu
    • University of Minnesota · Maple Grove, United StatesContact h•••@umn.edu · •••5978→f•••@umn.edu
    • University of North Carolina · Chapel Hill, United StatesContact a•••@neurology.unc.edu · •••8175→s•••@neurology.unc.edu
    • University of Pennsylvania · Philadelphia, United StatesContact p•••@pennmedicine.upenn.edu→d•••@pennmedicine.upenn.edu
    • Houston Methodist Hospital · Houston, United StatesContact added (no phone or email listed)
    • Children's Hospital of Westmead · Sydney, AustraliaContact person changed (no phone or email listed)
    • The Hospital for Sick Children · Toronto, CanadaContact none listed→•••6831
    • C. Besta Neurological Institute · Milan, ItalyContact d•••@istituto-besta.it · •••3001→e•••@istituto-besta.it
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01193088
Lead sponsor
University of Iowa
Responsible party
Michael Shy (Professor, University of Iowa) — Principal investigator
First posted
Sep 1, 2010
Start date
May 2010
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Tiffany Grider, MS, CGC
Contact
UICMTClinic@uiowa.edu
319-384-6362
Nicole Kressin, MSN, RN
Contact
UICMTClinic@uiowa.edu
319-384-6362
Michael E Shy, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion